Perceptive Informatics Enables Greater Trial Supply Efficiency With New Site Inventory Management Module

BOSTON, April 12, 2012 /PRNewswire/ -- Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today introduced the new Site Inventory Management Module of its ClinPhone® Randomization and Trial Supply Management (RTSM) solution. The RTSM technologies from Perceptive Informatics offer validated randomization methods, automated inventory control, dispensing and titration management, emergency code break capabilities, and supply reporting. This new web-based module is designed to improve the efficiency of clinical trial management by tracking the movement of supplies at clinical sites in real-time and streamlining workflow for site personnel.

The introduction of the Site Inventory Management Module reinforces a commitment by PAREXEL and Perceptive Informatics to help sponsors meet critical trial milestones and avoid delays due to lack of available study drug caused by late or incomplete arrival of clinical supplies at sites. Through advanced approaches and systems, the Company is focused on real-time confirmation of study supplies and allowing site investigators to more quickly begin using study drugs according to trial protocols. PAREXEL Clinical Logistics Services are supported by enabling technology solutions, including the ClinPhone RTSM solution.

The Site Inventory Management Module provides clinical site personnel with real-time study drug tracking information and efficient tools to take actions based on this information. Advanced features include visibility of drug expiration information, data filtering, simple selection and confirmation of actions, and multi-lingual capability.

"With greater clinical trial complexity, sites require the necessary tools for seamless access to data in order to make better, faster decisions," said Nick Richards, Vice President, Product Management, Perceptive Informatics. "With the introduction of this web-based module, we are enabling site teams to work in a more dynamic and interactive way, and bring more efficiency to trial supply chain processes."

The ClinPhone RTSM solution has been used in over 3,000 studies involving more than 289,000 sites and 1.7 million patients. The RTSM technologies provide sophisticated reporting to monitor trial management performance, trending and forecasting information, and in-depth data analysis. Clinical trials worldwide can be supported in multiple languages through the solution, which provides secure access, a detailed audit trail, transaction logging, and compliance with FDA 21 CFR Part 11.

For more information about the RTSM solution from Perceptive Informatics visit: http://www.perceptive.com/clinphone-rtsm/.

About Perceptive Informatics

Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. Perceptive enables customers to maximize the benefits of clinical trial technologies by providing flexible software-as-a-service (SaaS) applications and leading technology services. The Perceptive Informatics eClinical Suite is built on extensive medical and clinical expertise, as well as a deep understanding of the regulatory environment. The suite includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO).  The Perceptive Informatics eClinical Suite blurs the boundaries among systems that traditionally have been used in isolation, resulting in simplified workflow, improved efficiency and enhanced productivity. For more information about the integrated solutions in the Perceptive Informatics eClinical Suite visit www.perceptive.com.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 11,300 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $2.0 million in the third quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2011 as filed with the SEC on February 9, 2012, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, ClinPhone is a registered trademark of ClinPhone Limited, and Perceptive Informatics is a registered trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

SOURCE PAREXEL International Corporation